Results 131 to 140 of about 12,349 (241)

Angiotensin Converting Enzyme Inhibitor-related Angioedema: A Case of an Unexpected Death

Iranian Journal of Allergy, Asthma and Immunology, 2015
Angioedema is an asymmetric non-pitting oedema on face, lips, tongue and mucous membranes; any delay in diagnosis and treatment can be fatal. Treatment with lisinopril as an angiotensin converting enzyme (ACE) inhibitor, can be a reason of angioedema ...
Eray Atalay, Mehmet Tamer Özdemir, Gülşen Çiğsar, Ferhat Omurca, Nurullah Aslan, Mehmet Yildiz, Zehra Bahar Gey   +6 more
doaj  

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, Volume 183, Issue 9, Page 1779-1813, May 2026.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

Management of hereditary angioedema in pregnant women: a review

International Journal of Women's Health, 2014
Teresa Caballero,1,2 Julio Canabal,1 Daniela Rivero-Paparoni,1 Rosario Cabañas1 1Hospital La Paz Institute for Health Research, (IdiPaz) 2Biomedical Research Network on Rare Diseases-U754 (CIBERER), Madrid, Spain Abstract: Three types of ...
Caballero T, Canabal J, Rivero-Paparoni D, Cabañas R   +3 more
doaj  

Treatment of hereditary angioedema with plasma-derived C1 inhibitor

Therapeutics and Clinical Risk Management, 2008
Michael J Prematta, Tracy Prematta, Timothy J CraigSection of Allergy and Immunology, Penn State University, Milton S. Hershey Medical Center, PA, USABackground: Plasma-derived C1 inhibitor (C1-INH) concentrate is a treatment option for acute hereditary ...
Michael J Prematta, Tracy Prematta, Timothy J Craig   +2 more
doaj  

‘What’ and ‘How’ to Measure in Allergy and Clinical Immunology: A Systematic Review of Core Outcome Sets and Outcome Harmonisation Processes

Clinical &Experimental Allergy, Volume 56, Issue 5, Page 476-497, May 2026.
This systematic review maps core outcome sets and harmonisation efforts in allergy and clinical immunology. Despite shared priorities such as quality of life and symptoms, substantial gaps and methodological inconsistencies remain, underscoring the need for broader coverage and standardised outcome measurement to improve comparability and clinical ...
Anastasia Demidova, Nata Kiknavelidze, Kristine Purtskhvanidze, Elvina Alieva, Mehrshad Ebrahimnejad, Svetlana Konchina, Azaliya Nurmeeva, Igor Matkovskii, Elmira Elmurzaeva, Siuzanna Davtian, Natalia Degtyareva, Karl Philipp Drewitz, Alan Asmanov, Nikolina Banjanin, Erna Botjes, Pasquale Comberiati, Joana Costa, Derek K. Chu, Michelle M. Epstein, Lyudmila Fedorova, Audrey Dunn Galvin, Mattia Giovannini, Matthew Greenhawt, Kristina R. Jamalyan, Christina J. Jones, Ekaterina Khaleva, Rebecca C. Knibb, Yael A. Leshem, Douglas P. Mack, Isabel Mafra, Mary Jane Marchisotto, Dragan Mijakoski, Asel Nurtazina, Cevdet Özdemir, Diego Peroni, Jennifer L. P. Protudjer, Pablo Rodríguez del Río, Ann‐Marie Malby Schoos, Anita Fossaluzza Schopfer, Sasho Stoleski, Julia Upton, Willem van de Veen, Jon Genuneit, Robert J. Boyle, Christian Apfelbacher, Daniel Munblit   +45 more
wiley   +1 more source

The role of genetics in the current diagnostic workup of idiopathic non-histaminergic angioedema [PDF]

, 2018
Bova, Maria, Cicardi, Marco, Del Giacco, Stefano, Firinu, Davide, Loffredo, Stefania, Margaglione, Maurizio   +5 more
core   +1 more source

Supply and Demand in the Mathematics of Rare Disease Drug Development: Why Choosing the Right Model Is Crucial

Clinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT Clinical trials for rare diseases face a fundamental mathematical challenge that conventional randomized controlled trial (RCT) designs cannot overcome. With approximately 95% of the estimated 10,000–16,000 rare diseases lacking approved therapies, and drug development programs failing at rates exceeding 75% in non‐oncology indications, the ...
Marshall L. Summar, Janet Woodcock
wiley   +1 more source

Hereditary angioedema

Medicina Clínica (English Edition), 2015
Teresa, Caballero Molina, María, Pedrosa Delgado, Carmen, Gómez Traseira   +2 more
openaire   +3 more sources

Delayed urticaria during treatment with anti‐CGRP monoclonal antibodies in migraine

Headache: The Journal of Head and Face Pain, Volume 66, Issue 5, Page 1193-1199, May 2026.
Abstract Objective To characterize clinical presentation and management of urticaria associated with calcitonin gene‐related peptide (CGRP) ‐targeting monoclonal antibodies (mAbs) for migraine prophylaxis. Background CGRP‐targeting mAbs are effective in migraine prophylaxis, but have been associated with hypersensitivity reactions, including urticaria.
Christoph T. Berger, Federico Burguet Villena, Severin B. Vogt, Lukas Heydrich, Karin Hartmann, Athina Papadopoulou   +5 more
wiley   +1 more source

Hereditary angioedema: the plasma contact system out of control: comment [PDF]

, 2018
Loffredo, S., Marone, G.
core   +1 more source